NeuroPhage Nets $12.4M to Tackle Alzheimer’s and Other Brain Disorders

Score one for neurodegenerative disease therapies. Cambridge, Mass.-based NeuroPhage Pharmaceuticals said today it has closed $12.4 million in Series B financing led by Mérieux Développement, the healthcare investment arm of French firm Institut Mérieux.
Xconomy